Cargando…

MTHFR Polymorphism Is Associated With Severe Methotrexate-Induced Toxicity in Osteosarcoma Treatment

BACKGROUND: Previous studies have revealed the critical role of methylene tetrahydrofolate reductase (MTHFR) polymorphisms in response to high-dose methotrexate (MTX)-induced toxicity in osteosarcoma patients. However, the conclusions remain controversial. In this setting, we performed a meta-analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wenchao, Liu, Zhongyue, Yang, Zhimin, Feng, Chengyao, Zhou, Xiaowen, Tu, Chao, Li, Zhihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714641/
https://www.ncbi.nlm.nih.gov/pubmed/34976820
http://dx.doi.org/10.3389/fonc.2021.781386
_version_ 1784623949220413440
author Zhang, Wenchao
Liu, Zhongyue
Yang, Zhimin
Feng, Chengyao
Zhou, Xiaowen
Tu, Chao
Li, Zhihong
author_facet Zhang, Wenchao
Liu, Zhongyue
Yang, Zhimin
Feng, Chengyao
Zhou, Xiaowen
Tu, Chao
Li, Zhihong
author_sort Zhang, Wenchao
collection PubMed
description BACKGROUND: Previous studies have revealed the critical role of methylene tetrahydrofolate reductase (MTHFR) polymorphisms in response to high-dose methotrexate (MTX)-induced toxicity in osteosarcoma patients. However, the conclusions remain controversial. In this setting, we performed a meta-analysis to determine their association more precisely. METHOD: Eligible studies were searched and screened in PubMed, Web of Science, Cochrane Library, Clinical-Trials.gov, Embase, and China National Knowledge Infrastructure (CNKI) following specific inclusion and exclusion criteria. The required information was retrieved and collected for subsequent meta-analysis. Association between MTHFR polymorphism and MTX toxicity was evaluated by odds ratios (ORs). RESULTS: Seven studies containing 585 patients were enrolled and analyzed in this meta-analysis. Overall, the MTX related grade 3-4 liver toxicity was significantly associated with MTHFR rs1801133 allele (T vs. C: OR=1.61, 95%CI=1.07-2.42, P=0.024), homozygote (TT vs. CC: OR=2.11, 95%CI=1.06-4.21, P=0.011), and dominant genetic model (TT/TC vs. CC: OR=3.15, 95%CI=1.30-7.60, P=0.035) in Asian population. Meanwhile, close associations between MTX mediated grade 3-4 mucositis and MTHFR rs1801133 polymorphism were identified in allele contrast (T vs. C: OR=2.28, 95%CI=1.49-3.50, P<0.001), homozygote comparison (TT vs. CC: OR=4.07, 95%CI=1.76-9.38, P=0.001), heterozygote comparison (TC vs. CC: OR=2.55, 95%CI=1.20-5.42, P=0.015), recessive genetic model (TT vs. TC/CC: OR=2.09, 95%CI=1.19-3.67, P=0.010), and dominant genetic model (TT/TC vs. CC: OR=2.97, 95%CI=1.48-5.96, P=0.002). Additionally, kidney toxicity was corelated with the heterozygote comparison (TC vs. CC: OR=2.63, 95%CI=1.31-5.29, P=0.007) of rs1801133 polymorphism. CONCLUSION: The MTHFR rs1801133 polymorphism was significantly associated with severer liver toxicity induced by high-dose MTX treatment in the Asian population. In the meantime, patients with MTHFR rs1801133 polymorphism were predisposed to MTX- related mucositis.
format Online
Article
Text
id pubmed-8714641
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87146412021-12-30 MTHFR Polymorphism Is Associated With Severe Methotrexate-Induced Toxicity in Osteosarcoma Treatment Zhang, Wenchao Liu, Zhongyue Yang, Zhimin Feng, Chengyao Zhou, Xiaowen Tu, Chao Li, Zhihong Front Oncol Oncology BACKGROUND: Previous studies have revealed the critical role of methylene tetrahydrofolate reductase (MTHFR) polymorphisms in response to high-dose methotrexate (MTX)-induced toxicity in osteosarcoma patients. However, the conclusions remain controversial. In this setting, we performed a meta-analysis to determine their association more precisely. METHOD: Eligible studies were searched and screened in PubMed, Web of Science, Cochrane Library, Clinical-Trials.gov, Embase, and China National Knowledge Infrastructure (CNKI) following specific inclusion and exclusion criteria. The required information was retrieved and collected for subsequent meta-analysis. Association between MTHFR polymorphism and MTX toxicity was evaluated by odds ratios (ORs). RESULTS: Seven studies containing 585 patients were enrolled and analyzed in this meta-analysis. Overall, the MTX related grade 3-4 liver toxicity was significantly associated with MTHFR rs1801133 allele (T vs. C: OR=1.61, 95%CI=1.07-2.42, P=0.024), homozygote (TT vs. CC: OR=2.11, 95%CI=1.06-4.21, P=0.011), and dominant genetic model (TT/TC vs. CC: OR=3.15, 95%CI=1.30-7.60, P=0.035) in Asian population. Meanwhile, close associations between MTX mediated grade 3-4 mucositis and MTHFR rs1801133 polymorphism were identified in allele contrast (T vs. C: OR=2.28, 95%CI=1.49-3.50, P<0.001), homozygote comparison (TT vs. CC: OR=4.07, 95%CI=1.76-9.38, P=0.001), heterozygote comparison (TC vs. CC: OR=2.55, 95%CI=1.20-5.42, P=0.015), recessive genetic model (TT vs. TC/CC: OR=2.09, 95%CI=1.19-3.67, P=0.010), and dominant genetic model (TT/TC vs. CC: OR=2.97, 95%CI=1.48-5.96, P=0.002). Additionally, kidney toxicity was corelated with the heterozygote comparison (TC vs. CC: OR=2.63, 95%CI=1.31-5.29, P=0.007) of rs1801133 polymorphism. CONCLUSION: The MTHFR rs1801133 polymorphism was significantly associated with severer liver toxicity induced by high-dose MTX treatment in the Asian population. In the meantime, patients with MTHFR rs1801133 polymorphism were predisposed to MTX- related mucositis. Frontiers Media S.A. 2021-12-15 /pmc/articles/PMC8714641/ /pubmed/34976820 http://dx.doi.org/10.3389/fonc.2021.781386 Text en Copyright © 2021 Zhang, Liu, Yang, Feng, Zhou, Tu and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhang, Wenchao
Liu, Zhongyue
Yang, Zhimin
Feng, Chengyao
Zhou, Xiaowen
Tu, Chao
Li, Zhihong
MTHFR Polymorphism Is Associated With Severe Methotrexate-Induced Toxicity in Osteosarcoma Treatment
title MTHFR Polymorphism Is Associated With Severe Methotrexate-Induced Toxicity in Osteosarcoma Treatment
title_full MTHFR Polymorphism Is Associated With Severe Methotrexate-Induced Toxicity in Osteosarcoma Treatment
title_fullStr MTHFR Polymorphism Is Associated With Severe Methotrexate-Induced Toxicity in Osteosarcoma Treatment
title_full_unstemmed MTHFR Polymorphism Is Associated With Severe Methotrexate-Induced Toxicity in Osteosarcoma Treatment
title_short MTHFR Polymorphism Is Associated With Severe Methotrexate-Induced Toxicity in Osteosarcoma Treatment
title_sort mthfr polymorphism is associated with severe methotrexate-induced toxicity in osteosarcoma treatment
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714641/
https://www.ncbi.nlm.nih.gov/pubmed/34976820
http://dx.doi.org/10.3389/fonc.2021.781386
work_keys_str_mv AT zhangwenchao mthfrpolymorphismisassociatedwithseveremethotrexateinducedtoxicityinosteosarcomatreatment
AT liuzhongyue mthfrpolymorphismisassociatedwithseveremethotrexateinducedtoxicityinosteosarcomatreatment
AT yangzhimin mthfrpolymorphismisassociatedwithseveremethotrexateinducedtoxicityinosteosarcomatreatment
AT fengchengyao mthfrpolymorphismisassociatedwithseveremethotrexateinducedtoxicityinosteosarcomatreatment
AT zhouxiaowen mthfrpolymorphismisassociatedwithseveremethotrexateinducedtoxicityinosteosarcomatreatment
AT tuchao mthfrpolymorphismisassociatedwithseveremethotrexateinducedtoxicityinosteosarcomatreatment
AT lizhihong mthfrpolymorphismisassociatedwithseveremethotrexateinducedtoxicityinosteosarcomatreatment